WADA Prohibited is a recurring topic in our peptide coverage. This hub collects every article tagged WADA Prohibited, newest first, each evidence-graded and tied to real, verifiable sources.
The anchor safety guide to the peptide class — separating what the molecule does from what is actually in the vial, with the load-bearing contraindications, interactions, injection risks, and the shifting 2026 FDA/WADA landscape.
What peptides actually are, how they differ from drugs, hormones and supplements, the major functional classes, and — crucially — what the human evidence does and doesn't support, from Grade-A medicines to Grade C-D research peptides.
A clinical explainer separating true peptides from the SARMs, small-molecule drugs, hormones, and supplements sold beside them on the same gray-market storefronts. Chemistry, evidence, FDA status, and anti-doping rules are all class-specific.
A single, evidence-graded map of what the published literature actually shows for the peptide field — separating the handful of Grade-A, FDA-approved peptides from the much larger group whose claims rest on animal data, mechanism, or marketing alone.
Wound healing is one of the few peptide areas with genuine human controlled-trial data — but it is narrow, topical, and concentrated in chronic wounds. A clinical-editorial ranking of GHK-Cu, thymosin β4, LL-37 and BPC-157 by what the evidence actually supports in 2026.
A source-cited definitional reference to the vocabulary of peptide, hormone, and longevity science — from receptor pharmacology and pharmacokinetics to manufacturing quality and the U.S. and anti-doping regulatory landscape.
"Legal" is not one question but five — FDA approval, compounding eligibility, DEA scheduling, WADA sport status, and state telehealth law. A date-stamped 2026 explainer of where peptides actually stand.
An evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
A clinical, evidence-first ranking of the peptides most promoted for healing surgical incisions and preventing scars — separating genuine human topical-wound data from animal-only signals and marketing.
The peptides with real human evidence for raising or protecting endogenous testosterone are the classical reproductive gonadotropins — hCG and LH/FSH — not the boutique 'natural testosterone' research peptides. A ranked, evidence-graded review for 2026.
Tendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
A clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
An evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
An evidence-graded review of the peptides marketed for osteoarthritis and joint degeneration. The honest 2026 verdict: the strongest human data belongs not to any joint-repair peptide but to GLP-1 metabolic drugs that relieve knee-OA pain by removing mechanical load.
A clinical, evidence-graded ranking of the peptides marketed for neuroprotection — Cerebrolysin, Semax, ARA-290, SS-31/elamipretide and P021 — separating a modest, mixed human signal from elegant but preclinical-only mechanism.
A clinical, evidence-graded ranking of the peptides studied for nerve injury and neuropathy — ARA-290, Cerebrolysin, BPC-157 and Cortagen — separating genuine human RCT data from animal-only signal.
An evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
A clinical, evidence-graded review of the peptides marketed for hamstring pulls, calf and quad strains, and muscle tears — where the animal data are genuinely muscle-specific, and why no completed human trial yet proves any of them heals a strain.
An evidence-graded review of the peptides marketed for muscle growth and lean mass — follistatin, CJC-1295, ipamorelin, MGF and IGF-1 LR3. The honest 2026 verdict: no peptide has Grade A human muscle-outcome data, and every one is prohibited in sport by WADA.
A clinical, evidence-first ranking of the peptides marketed for mitochondrial dysfunction — elamipretide (SS-31), MOTS-c, humanin and the SHLP family. Only one has any human bioenergetic data, and even that was acute and reversible.
WADA Prohibited is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged WADA Prohibited, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.